Figure 1.
ERG measurements of all groups, control, untreated ischemic, and the VEGF treated ones (beva and rani), were performed. The recording at a light intensity of 3 cd·s/m2 is pictured. (A) A significant decrease of the a-wave amplitude was observed in the ischemic group (p = 0.007) compared to control. The bevacizumab- (p = 0.06) and ranibizumab-treated groups (p = 0.32) showed a lesser reduced amplitude at this light intensity, when compared to control eyes; (B) Additionally, the b-wave amplitude was lower in all ischemic eyes, the untreated (p < 0.001) and the anti-VEGF treated ones (p < 0.001), in comparison to the control group. The b-wave amplitude of the ranibizumab-treated group was less diminished as well. A significant increase of the amplitude could be detected here in comparison to the ischemic group (p = 0.03). *: p < 0.05; **: p < 0.01; ***: p < 0.001. Abbreviations: Beva: bevacizumab, Rani: ranibizumab. n = 5–6/group.